» Articles » PMID: 15994959

Malignant Transformation but Not Normal Cell Growth Depends on Signal Transducer and Activator of Transcription 3

Overview
Journal Cancer Res
Specialty Oncology
Date 2005 Jul 5
PMID 15994959
Citations 59
Authors
Affiliations
Soon will be listed here.
Abstract

Signal transducer and activator of transcription 3 (STAT3) has been indirectly implicated in numerous fundamental cellular processes, including proliferation, survival, and differentiation. We provide genetic evidence from studies of STAT3-null cells that STAT3 is dispensable for normal growth of mouse fibroblasts in culture. STAT3 contributed to the full induction of some (typified by c-fos) but not all (typified by c-myc) immediate early gene expression, but STAT3-independent processes were sufficient to support full cell growth and survival. However, STAT3 was required to manifest a transformed state following expression of v-src, and STAT3-null cells were impaired for anchorage-independent growth as colonies in soft agar and as tumors in mice. The data suggest that STAT3 mediates the maintenance of focal adhesion kinase activity in the absence of cell adhesion by suppressing the action of an inhibitory phosphatase.

Citing Articles

STAT3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway.

Pencik J, Philippe C, Schlederer M, Atas E, Pecoraro M, Grund-Groschke S Mol Cancer. 2023; 22(1):133.

PMID: 37573301 PMC: 10422794. DOI: 10.1186/s12943-023-01825-8.


Senescent Fibroblasts Generate a CAF Phenotype through the Stat3 Pathway.

Li H, Qiu L, Liu Q, Ma Z, Xie X, Luo Y Genes (Basel). 2022; 13(9).

PMID: 36140747 PMC: 9498467. DOI: 10.3390/genes13091579.


Anoikis resistance in diffuse glioma: The potential therapeutic targets in the future.

Zhu Z, Fang C, Xu H, Yuan L, Du Y, Ni Y Front Oncol. 2022; 12:976557.

PMID: 36046036 PMC: 9423707. DOI: 10.3389/fonc.2022.976557.


Targeted Therapy of B7 Family Checkpoints as an Innovative Approach to Overcome Cancer Therapy Resistance: A Review from Chemotherapy to Immunotherapy.

Taghavi B, Alizadeh N, Saeedi H, Ahangar N, Derakhshani A, Hajiasgharzadeh K Molecules. 2022; 27(11).

PMID: 35684481 PMC: 9182385. DOI: 10.3390/molecules27113545.


Multicellular Effects of STAT3 in Non-small Cell Lung Cancer: Mechanistic Insights and Therapeutic Opportunities.

Parakh S, Ernst M, Poh A Cancers (Basel). 2021; 13(24).

PMID: 34944848 PMC: 8699548. DOI: 10.3390/cancers13246228.


References
1.
Broome M, Courtneidge S . No requirement for src family kinases for PDGF signaling in fibroblasts expressing SV40 large T antigen. Oncogene. 2000; 19(24):2867-9. DOI: 10.1038/sj.onc.1203608. View

2.
Jones R, Brunton V, Frame M . Adhesion-linked kinases in cancer; emphasis on src, focal adhesion kinase and PI 3-kinase. Eur J Cancer. 2000; 36(13 Spec No):1595-606. DOI: 10.1016/s0959-8049(00)00153-2. View

3.
Blake R, Broome M, Liu X, Wu J, Gishizky M, Sun L . SU6656, a selective src family kinase inhibitor, used to probe growth factor signaling. Mol Cell Biol. 2000; 20(23):9018-27. PMC: 86555. DOI: 10.1128/MCB.20.23.9018-9027.2000. View

4.
Martin G . The hunting of the Src. Nat Rev Mol Cell Biol. 2001; 2(6):467-75. DOI: 10.1038/35073094. View

5.
Bowman T, Broome M, Sinibaldi D, Wharton W, Pledger W, Sedivy J . Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc Natl Acad Sci U S A. 2001; 98(13):7319-24. PMC: 34666. DOI: 10.1073/pnas.131568898. View